Jaguar Health

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jaguar Health reports revenue growth and eyes cancer therapy market

Jaguar Health's Q1 2024 performance showed revenue growth and improved financial metrics. The company's strategic focus on cancer supportive care and rare diseases positions it for future growth. Challenges include trial result uncertainties and regulatory timelines, but opportunities exist in market expansion and new programs.

Jaguar Health reports revenue growth and promising clinical trial results

Jaguar Health's Q2 2024 earnings call showcases revenue growth, positive clinical trial outcomes, and strategic plans for product launches and FDA discussions. The company's focus on improving patient outcomes and expanding its product reach positions it for future success in the healthcare market.

Jaguar Health reports revenue growth and advances in cancer care

Jaguar Health's Q3 performance reflects revenue growth, successful trial outcomes, and a focus on cancer patient care through innovative products.
While facing challenges in regulatory processes and financial metrics, the company is well-positioned to capitalize on opportunities in rare diseases and oncology.
Overall, Jaguar Health's strategic initiatives and commitment to addressing critical medical needs position it for potential growth and impact in the healthcare sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. It operates through the Human Health and Animal Health segments. The Human Health segment is involved in manufacturing human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment includes commercializing prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Registration link for webcast appears below SAN FRANCISCO, CA / ACCESSWIRE / June 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that an Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC S.p.A. ("Dragon SPAC") founding sponsor Josh Mailman will air this Thursday, June 3, 2021, at 8:30 AM Eastern Time.

REMINDER: Innovators with Jane King Webcast Interview with Jaguar Health CEO Lisa Conte & Dragon SPAC Founding Sponsor Josh Mailman to Take Place Thursday, June 3, 2021 at 8:30 AM Eastern

Today, a variety of factors are taking investors in JAGX stock on a very nice ride, as the company made a couple key announcements. The post JAGX Stock: 2 Big Reasons Jaguar Health Is Climbing Higher Today appeared first on InvestorPlace.

JAGX Stock: 2 Big Reasons Jaguar Health Is Climbing Higher Today

Jaguar & Dragon SPAC announce initial funding of $10.8 million into Dragon SPAC Napo EU to focus initially on conditional approval for an important orphan indication, short bowel syndrome (SBS), a condition leading to intestinal failure Innovators with Jane King webcast interview with Jaguar CEO Lisa Conte & Dragon SPAC founding sponsor Josh Mailman to take place Thursday, June 3rd at 8:30 AM Eastern Registration link for webcast appears below Equita Group S.p.A., a leading Italian based investment bank, advising Dragon SPAC; Cantor Fitzgerald & Co. advising Jaguar on non-deal related activities SAN FRANCISCO, CA & MILAN, ITALY / ACCESSWIRE / June 1, 2021 / Napo EU S.p.A.

Napo EU S.p.A., Jaguar Health's Italian Subsidiary, Provides Updates on Plans to Pursue Conditional Marketing Authorization in the EU

Napo EU S.p.A., named target of Dragon SPAC, provides update on plan to pursue conditional marketing authorization for crofelemer in EU Equita Group S.p.A.

Jaguar Health & Dragon SPAC Announce Initial Funding of US$10.8 Million into Dragon SPAC

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 11.84% today. This is why it happened.

JAGX Stock Price: 11.84% Increase Explanation

Investors in JAGX stock are having a solid week, after the company made a few key announcements that have taken this stock higher. The post JAGX Stock: Why Jaguar Health Is Climbing Higher Today appeared first on InvestorPlace.

JAGX Stock: Why Jaguar Health Is Climbing Higher Today

SAN FRANCISCO, CA / ACCESSWIRE / May 26, 2021 / Napo Pharmaceuticals Inc., the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), announced today the appointment of Darlene Horton, M.D., a biopharmaceutical veteran and leading clinical development expert, to the role of Chief Medical Officer (CMO) for Napo.

Napo Pharmaceuticals, Jaguar Health's Subsidiary, Bolsters Management Team with Appointment of Darlene Horton, M.D. as Chief Medical Officer

Shares of Jaguar Health and JAGX stock are once again on the move today as investors price in the academic results submitted late last week. The post JAGX Stock: Why Jaguar Health Is Soaring on Monday appeared first on InvestorPlace.

JAGX Stock: Why Jaguar Health Is Soaring on Monday

Ashford Hospitality Trust

Obalon Therapeutics

Are these the best penny stocks to watch right now? Take a look and decide for yourself The post Penny Stocks Are Heating Up, Here's 3 You Need to Know About appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks Are Heating Up, Here's 3 You Need to Know About

The stock price of Jaguar Health Inc (NASDAQ: JAGX) increased by 6.4% on Friday, May 21. This is why it happened.

JAGX Stock Price: 6.4% Increase Explanation

Cyclerion Therapeutics Inc

Kaixin Auto Holdings

After this week's market pullback, some of these penny stocks are trending into the weekend. The post Best Penny Stocks To Buy Right Now?

Best Penny Stocks To Buy Right Now? 3 To Know Before Next Week

SAN FRANCISCO, CA / ACCESSWIRE / May 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced the highlights of the abstract regarding patient outcomes associated with cancer-related diarrhea ("CRD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. In addition, two CRD-related abstracts from Napo and its collaborators have been accepted for online publication at ASCO.

Jaguar Health and Napo Pharmaceuticals Provide Key Findings from Cancer-related Diarrhea Abstracts Submitted to ASCO for June 2021 Annual Meeting

Newly created Jaguar Health Community Instagram page introduces jaguar-themed contest SAN FRANCISCO, CA / ACCESSWIRE / May 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company recently launched a new social media channel for stakeholders and the Company's growing community of followers. The ‘Jaguar Health Community' Instagram page will serve as a central social media communications hub for all community-building and educational awareness activities.

Jaguar Health Announces the Launch of a New Social Media Channel Dedicated to Reaching the Growing Jaguar Health Community

Canalevia would be first and only FDA-approved plant-based medicine for dogs that suffer from diarrhea during chemotherapy Canalevia will be available by fourth quarter 2021, if conditionally approved SAN FRANCISCO, CA / ACCESSWIRE / May 18, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided updates regarding the development program for the Company's oral plant-based drug candidate Canalevia™ (crofelemer delayed-release tablets) to treat chemotherapy-induced diarrhea (CID) in dogs and exercise-induced diarrhea (EID) in dogs. There currently is no FDA-approved anti-secretory prescription product to manage these types of debilitating diarrhea in dogs.

Jaguar Health Provides Updates on Canalevia (Crofelemer), the First Plant-based Prescription Medicine Under Development for Chemotherapy-induced Diarrhea in Dogs and Exercise-induced Diarrhea in Dogs

Jaguar Health, Inc. (JAGX) CEO Lisa Conte on Q1 2021 Results - Earnings Call Transcript

Shares of Jaguar Health (NASDAQ:JAGX) decreased 1.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 83.93% year over year to ($0.09), which missed the estimate of ($0.02).

Recap: Jaguar Health Q1 Earnings

First quarter 2021 Mytesi gross sales and net sales were approximately $4.6 million and approximately $1.2 million, increases of 250% and 43%, respectively Company to host investor webcast Monday, May 17th at 8:30 a.m. Eastern regarding first quarter 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 17, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated first quarter 2021 financial results.

Jaguar Health, Inc. Reports 2021 First Quarter Financial Results

Based on a preliminary review of votes cast, over 80% have voted in favor of Proposals 2, 3, 4 & 6 Meeting scheduled to reconvene June 11, 2021 at 8:30 AM Pacific Standard Time to provide time to reach quorum Reminder: Jaguar to host investor webcast Monday, May 17th at 8:30 AM Eastern Time regarding Q1 2021 financials & business updates SAN FRANCISCO, CA / ACCESSWIRE / May 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that its Annual Meeting of Stockholders held on May 13, 2021 (the "Annual Meeting") was adjourned due to a lack of quorum. The adjourned meeting will be held at 8:30 a.m.

Jaguar Health Announces Adjournment of Annual Meeting of Stockholders Until Friday, June 11, 2021 and Encourages All Shareholders to Vote

Webcast registration link appears below Company plans to file Q1 2021 10-Q on May 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / May 11, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17, 2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.

Jaguar Health to Host Investor Webcast Monday, May 17th at 8:30 AM Eastern Time Regarding Q1 2021 Financials & Business Updates

American Resources Corp

Cinedigm

Ault Global Holdings

Cenntro Electric Group

Precipio

Support.com

So, which Reddit penny stocks with ambitious plans could pay off down the road? Consider these seven high-risk, high-potential plays as ones where risk/return leans in your favor: The post 7 Reddit Penny Stocks With Interesting Plans appeared first on InvestorPlace.

7 Reddit Penny Stocks With Interesting Plans

Company terminates at-the-market (ATM) financing program SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement (the "Transaction") with North American institutional investors for the purchase and sale of 7,647,000 shares of common stock for gross proceeds of approximately $10.8 million in a registered direct offering. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent in connection with the Transaction.

Jaguar Health Announces $10.8 Million Registered Direct Offering for the Benefit of Napo EU Business Plan

SAN FRANCISCO, CA / ACCESSWIRE / April 29, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced the title of the abstract regarding patient outcomes associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc. ("Napo"), Jaguar's wholly owned subsidiary, and Napo's collaborators that has been accepted for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held virtually from June 4-8, 2021. The title of the accepted poster presentation is: The impact of cancer-related diarrhea on changes in cancer therapy patterns: Real world evidence Poster Session: Symptoms and Survivorship The lead author of the study is Pablo C.

Jaguar Health and Napo Pharmaceuticals Announce Title of Abstract Regarding Patient Outcomes Associated with Cancer Therapy-Related Diarrhea Accepted for Poster Presentation at the American Society of Clinical Oncology 2021 Annual Meeting

ConforMIS

Zomedica

Creating a penny stock watchlist? You should check these 3 out The post Best Penny Stocks to Buy?

Best Penny Stocks to Buy? You Might Want to Add These 3 To Your Watchlist

Registration link for webcast interview appears below SAN FRANCISCO, CA / ACCESSWIRE / April 21, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today about the Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, and Josh Mailman, the lead sponsor of the Dragon special purpose acquisition company (the "Dragon SPAC"), that will air during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.

REMINDER FROM JAGUAR HEALTH: Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., Jaguar's New Italian Subsidiary

Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that an Innovators with Jane King interview of Lisa Conte, the Company's founder, president, and CEO, will be aired during a webcast this Friday, April 23, 2021, at 8:30 AM Eastern to provide a business overview of Napo EU S.p.A. ("Napo EU"), Jaguar's wholly owned Italian subsidiary.

Jaguar Health Announces Innovators with Jane King Webcast Interview to Take Place Friday, April 23, 2021 at 8:30 AM Eastern to Provide a Business Overview of Napo EU S.p.A., the Company's New Italian Subsidiary

News for Jaguar Health Stock (JAGX)